Piper Sandler Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $16
H.C. Wainwright Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $10
Evercore Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $7
Evercore ISI Remains a Buy on Savara (SVRA)
Savara Announces Patient Journey Map for People Living With Autoimmune Pulmonary Alveolar Proteinosis (APAP) Accepted for Poster Presentation at the CHEST 2024 Annual Meeting
Savara Price Target Maintained With a $10.00/Share by HC Wainwright & Co.